[{"orgOrder":0,"company":"Pheno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PTD802","moa":"GPR17","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pheno Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Pheno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pheno Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Pheno Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : PTD802 is a novel small molecule therapeutic designed to promote remyelination by inhibiting GPR17. It is being investigated for multiple sclerosis.

                          Product Name : PTD802

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 14, 2025

                          Lead Product(s) : PTD802

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank